Browsing Tag
NASDAQ
475 posts
Why Smart Powerr Corp.’s $2m stock offering is putting CREG dilution risk back in focus
Smart Powerr Corp. raised $2 million through a stock offering at $0.45 per share. Find out what the deal means for CREG dilution risk and investor sentiment.
Alkami Technology’s MANTL partnership with FVSBank signals a sharper deposit growth push for community banks
Community banks are fighting deposit leakage. Alkami’s MANTL deal with FVSBank shows why account opening speed now matters. Read more.
BioMarin’s BMN 401 setback raises regulatory questions after ENPP1 deficiency trial meets only one endpoint
BioMarin moved the biomarker, not the rickets score. BMN 401 now tests how much regulators will accept in ultra-rare disease trials.
From diagnostics to drone warfare: Why Quantum Cyber’s pivot is getting harder to ignore
Quantum Cyber has a drone-war story investors like. The real test is whether QUCY can turn defense positioning into contracts.
Faraday Future raises $25m as FFAI bets on robotics pivot after years of liquidity pressure
Faraday Future has fresh cash and an AI robotics pivot. The real test is whether FFAI can turn funding into execution.
Regeneron Pharmaceuticals’ LAG-3 gamble stumbles as Keytruda remains hard to beat in melanoma
Regeneron showed a PFS signal but missed the statistical bar. Keytruda remains the oncology benchmark investors still have to beat.
Why DayOne’s $5bn IPO plan could become Singapore’s biggest capital-market test in years
AI needs data centres, but capital needs liquidity. DayOne’s planned dual listing could test Singapore’s Nasdaq bridge at scale.
BlackRock could anchor SpaceX IPO demand as valuation talk reaches $1.75tn
SpaceX may test IPO history. BlackRock’s reported billions could decide whether private-market hype survives public scrutiny.
ImmunityBio targets U.S. BCG shortage with exclusive Tokyo-172 agreement and FDA pathway plan
BCG supply is still a U.S. bladder cancer bottleneck. ImmunityBio’s Tokyo deal could widen access, if regulators move with it.
SpaceX looks closer than ever to Wall Street, so why are bettors still skeptical?
SpaceX may be racing toward Nasdaq, but bettors still see timing risk. The May filing deadline could decide IPO momentum.